A Study to Evaluate the Effect of Pharmacokinetics (PK) of Acalabrutinib and Its Active Metabolite (ACP-5862) When Administered Alone and With Moderate CYP3A4 Inhibitors Fluconazole or Isavuconazole in Healthy Adult Participants

Inclusion Criteria: * Continuous non-smoker participant who has not used nicotine-containing products for at least 3 months prior to the first dosing and throughout the study * Have body mass index of \>= 18 kg/m\^2 and \<= 32 kg/m\^2 at screening * Medically healthy with no clinically significant medical history, physical examination, laboratory profiles, vital signs, or ECGs, as deemed by the principal investigator (PI) * Women participants must be of non-childbearing status and must have undergone the protocol specified sterilization procedures, and have official documentation, at least 6 months prior to the first dose; or be postmenopausal with amenorrhea for at least 1 year prior to the first dose and follicle-stimulating hormone serum levels consistent with postmenopausal status * Male participants must be willing to use protocol specified contraception methods * Male participants must agree not to donate sperm from the first dosing until 90 days after the last dosing * Ability to swallow multiple capsules and/or tablets using size 0 blank capsules (up to a maximum of 3 capsules per participant) Exclusion Criteria: * Participant is mentally or legally incapacitated or has significant emotional problems at the time of the screening visit or expected during the conduct of the study * History or presence of clinically significant medical or psychiatric condition or disease in the opinion of the PI or designee * History of any illness that, in the opinion of the PI, migh…